A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan
Study Details
- Hemophilia A
- Drug: Efanesoctocog alfa
- Inclusion Criteria:
- Participants with all ages and diagnosis of moderate-severe hemophilia A without current and/or at least three years of un-detectable inhibitor (\<0.6 BU)
- Participants with moderate to severe hemophilia A as defined by FVIII level ≤ 5%
- Participants starting efanesoctocog alfa prophylaxis treatment as per standard of care no more than three months prior to the enrollment date
- Participants aged 6 years and older are able to undergo MRI examinations (sedation given, if necessary, and per investigator discretion)
- Participants are able to undergo joint examinations
- Physician's decision to treat the participant with efanesoctocog alfa is made prior to and independently of participation in the study
- Signed and dated informed consent provided by the participant, or by the participant's legally acceptable representative for participants under the legal age before any study-related activities are undertaken. Assent should be obtained for pediatric participants according to local regulations
- Exclusion Criteria:
- Participants with coagulation disorders other than hemophilia A
- Participants diagnosed with other known bleeding disorder
- Participants currently receive factor therapy and have signs of decreased response to FVIII therapy
- Participants with a baseline Radiological Pettersson score (PS) of greater than 6 for each individual ankle
- Enrollment in another concurrent clinical interventional study, or intake of an Investigational Medicinal Product within 3 months prior to inclusion in this study
- Pregnant female participants
- The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Protocol Summary
This study is looking at how safe it is to switch from emicizumab to Mim8, in people with haemophilia A. Mim8 is a new medicine that is used to prevent bleeding episodes in people with haemophilia A. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). Mim8 will be injected under the skin using a pen-injector either once every week, once every two weeks or once every month. The participants will be trained in using the pen injector. The participants can choose themselves, in collaboration with the study doctor how often they get Mim8 in this study. When the participant will get their first Mim8 injection depends on their current treatment with emicizumab. The participants will get their first Mim8 injection at Visit 2. Participants will have between 6 and 27 Mim8 injections. The total number of injections participants will have depends on their dosing frequency. The study will last for about 6-12 months. While taking part in this study, there are some restrictions about what medicine participant can use. The study doctor will tell the participants more about this. In case the participants experience bleeds, these can be treated with additional haemostatic medicine as agreed with the study doctor. Female participants cannot take part if they are pregnant, breast-feeding or plan to get pregnant during the study period.